HomeMedicine
Medicine
Use of Tirzepatide Shown to Improve Sleep Apnea and Cardiovascular Outcomes
SURMOUNT-OSA Study Highlights Potential Dual-Action Benefits of Novel Therapy for Obesity
ORLANDO, Fla., June 21, 2024 /PRNewswire/ -- Today, findings from the SURMOUNT-OSA, a study of tirzepatide in patients with obstructive sleep apnea (OSA) and obesity, were announced, revealing significant improvements in both sleep apnea...
Common Cholesterol-Lowering Drug Found to Slow Vision Loss in Diabetes Patients
First-of-Its-Kind Study Shows Fenofibrate Reduces Eye Disease Progression by 27%
ORLANDO, Fla., June 21, 2024 /PRNewswire/ -- Today, findings from the Lowering Events in Non-proliferative retinopathy in Scotland (LENS) Trial revealed that fenofibrate, a medication used for many years to reduce blood fat levels, significantly reduces...
Expanded FORWARD Trial Demonstrates Continued Potential for Stem Cell-Derived Islet Cell Therapy to Eliminate Need for Insulin for People with T1D
American Diabetes Association Symposium Shows Patients with Type 1 Diabetes Experienced Insulin Independence and Elimination of Severe Hypoglycemic Events with Novel Therapy
ORLANDO, Fla., June 21, 2024 /PRNewswire/ -- Today, new data from the Phase 1/2 FORWARD clinical study of the VX-880 islet cell therapy...
Lilly’s tirzepatide reduced obstructive sleep apnea (OSA) severity, with up to 51.5% of participants meeting the criteria for disease resolution
In the primary endpoint, tirzepatide reduced moderate-to-severe OSA severity by up to 62.8% (about 30 fewer events per hour)
In a key secondary endpoint from two clinical studies, 43.0% and 51.5% of participants taking tirzepatide at the highest dose reached the criteria for disease resolution as...
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANDOVER, Mass., June 21, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on June 18, 2024, TransMedics granted non-qualified stock options to...
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, June 21, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs), today announced that on June 20, 2024, the Human Capital Management Committee of Avidity's Board of Directors...